scholarly journals Screening the Pathogen Box for Molecules Active against Plasmodium Sexual Stages Using a New Nanoluciferase-Based Transgenic Line of P. berghei Identifies Transmission-Blocking Compounds

2018 ◽  
Vol 62 (11) ◽  
Author(s):  
Juliana Calit ◽  
Irina Dobrescu ◽  
Xiomara A. Gaitán ◽  
Miriam H. Borges ◽  
Marisé S. Ramos ◽  
...  
Keyword(s):  
High Throughput Screening ◽  
Transmission Blocking ◽  
Content Type ◽  
Content Model ◽  
Mortality Burden ◽  
Membrane Feeding ◽  
Sexual Stages ◽  
Membrane Feeding Assay ◽  
Insight Into ◽  
Mosquito Infection

ABSTRACT Malaria remains an important parasitic disease with a large morbidity and mortality burden. Plasmodium transmission-blocking (TB) compounds are essential for achieving malaria elimination efforts. Recent efforts to develop high-throughput screening (HTS) methods to identify compounds that inhibit or kill gametocytes, the Plasmodium sexual stage infectious to mosquitoes, have yielded insight into new TB compounds. However, the activities of these compounds against gametes, formed in the first minutes of mosquito infection, are typically not assessed, unless screened in a standard membrane feeding assay, a labor-intensive assay. We demonstrate here the generation of a Plasmodium model for drug screens against gametes and fertilization. The new P. berghei line, named Ookluc, was genetically and pharmacologically validated and scalable for HTS. Screening the Pathogen Box from the Medicines for Malaria Venture using the new model identified promising TB compounds. The use of Ookluc in different libraries of compounds may aid in the identification of transmission-blocking drugs not assessed in screens against asexual stages or gametocytes.

scholarly journals Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds

2013 ◽  
Vol 81 (6) ◽  
pp. 1984-1989 ◽  
Author(s):  
Dari F. Da ◽  
Saurabh Dixit ◽  
Jetsumon Sattabonkot ◽  
Jianbing Mu ◽  
Luc Abate ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Burkina Faso ◽  
Phase 1 ◽  
Transmission Blocking ◽  
Content Type ◽  
Phase 1 Trial ◽  
Membrane Feeding ◽  
Geographical Regions ◽  
Reducing Activity ◽  
Membrane Feeding Assay

ABSTRACTPfs25 is a leading candidate for a malaria transmission-blocking vaccine whose potential has been demonstrated in a phase 1 trial with recombinant Pfs25 formulated with Montanide ISA51. Because of limited sequence polymorphism, the anti-Pfs25 antibodies induced by this vaccine are likely to have transmission-blocking or -reducing activity against most, if not all, field isolates. To test this hypothesis, we evaluated transmission-blocking activities by membrane feeding assay of anti-Pfs25 plasma from the Pfs25/ISA51 phase 1 trial againstPlasmodium falciparumparasites from patients in two different geographical regions of the world, Thailand and Burkina Faso. In parallel, parasite isolates from these patients were sequenced for the Pfs25 gene and genotyped for seven microsatellites. The results indicate that despite different genetic backgrounds among parasite isolates, the Pfs25 sequences are highly conserved, with a single nonsynonymous nucleotide polymorphism detected in 1 of 41 patients in Thailand and Burkina Faso. The anti-Pfs25 immune plasma had significantly higher transmission-reducing activity against parasite isolates from the two geographical regions than the nonimmune controls (P< 0.0001).

scholarly journals Functional Comparison of Plasmodium falciparum Transmission-Blocking Vaccine Candidates by the Standard Membrane-Feeding Assay

2013 ◽  
Vol 81 (12) ◽  
pp. 4377-4382 ◽  
Author(s):  
Kazutoyo Miura ◽  
Eizo Takashima ◽  
Bingbing Deng ◽  
Gregory Tullo ◽  
Ababacar Diouf ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Recombinant Proteins ◽  
The Other ◽  
Enzyme Linked Immunosorbent Assay ◽  
Dependent Manner ◽  
Feeding Assay ◽  
Transmission Blocking ◽  
Content Type ◽  
Membrane Feeding ◽  
Membrane Feeding Assay

ABSTRACTRecently, there has been a renewed interest in the development of transmission-blocking vaccines (TBV) againstPlasmodium falciparummalaria. While several candidate TBVs have been reported, studies directly comparing them in functional assays are limited. To this end, recombinant proteins of TBV candidates Pfs25, Pfs230, and PfHAP2 were expressed in the wheat germ cell-free expression system. Outbred CD-1 mice were immunized twice with the antigens. Two weeks after the second immunization, IgG levels were measured by enzyme-linked immunosorbent assay (ELISA), and IgG functionality was assessed by the standard membrane-feeding assay (SMFA) using culturedP. falciparumNF54 gametocytes andAnopheles stephensimosquitoes. All three recombinant proteins elicited similar levels of antigen-specific IgG judged by ELISA. When IgGs purified from pools of immune serum were tested at 0.75 mg/ml in the SMFA, all three IgGs showed 97 to 100% inhibition in oocyst intensity compared to control IgG. In two additional independent SMFA evaluations, anti-Pfs25, anti-Pfs230, and anti-PfHAP2 IgGs inhibited oocyst intensity in a dose-dependent manner. When all three data sets were analyzed, anti-Pfs25 antibody showed significantly higher inhibition than the other two antibodies (P< 0.001 for both), while there was no significant difference between the other two (P= 0.15). A proportion of plasma samples collected from adults living in an area of malaria endemicity in Mali recognized Pfs230 and PfHAP2. This is the first study showing that the HAP2 protein ofP. falciparumcan induce transmission-blocking antibody. The current study supports the possibility of using this system for a comparative study with multiple TBV candidates.

scholarly journals Salinomycin and Other Ionophores as a New Class of Antimalarial Drugs with Transmission-Blocking Activity

2015 ◽  
Vol 59 (9) ◽  
pp. 5135-5144 ◽  
Author(s):  
Sarah D'Alessandro ◽  
Yolanda Corbett ◽  
Denise P. Ilboudo ◽  
Paola Misiano ◽  
Nisha Dahiya ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Drug Target ◽  
Stage Iv ◽  
Stage Ii ◽  
Transmission Blocking ◽  
Content Type ◽  
New Class ◽  
Blocking Activity ◽  
Sexual Stages

ABSTRACTThe drug target profile proposed by the Medicines for Malaria Venture for a malaria elimination/eradication policy focuses on molecules active on both asexual and sexual stages ofPlasmodium, thus with both curative and transmission-blocking activities. The aim of the present work was to investigate whether the class of monovalent ionophores, which includes drugs used in veterinary medicine and that were recently proposed as human anticancer agents, meets these requirements. The activity of salinomycin, monensin, and nigericin onPlasmodium falciparumasexual and sexual erythrocytic stages and on the development of thePlasmodium bergheiandP. falciparummosquito stages is reported here. Gametocytogenesis of theP. falciparumstrain 3D7 was inducedin vitro, and gametocytes at stage II and III or stage IV and V of development were treated for different lengths of time with the ionophores and their viability measured with the parasite lactate dehydrogenase (pLDH) assay. The monovalent ionophores efficiently killed both asexual parasites and gametocytes with a nanomolar 50% inhibitory concentration (IC50). Salinomycin showed a fast speed of kill compared to that of standard drugs, and the potency was higher on stage IV and V than on stage II and III gametocytes. The ionophores inhibited ookinete development and subsequent oocyst formation in the mosquito midgut, confirming their transmission-blocking activity. Potential toxicity due to hemolysis was excluded, since only infected and not normal erythrocytes were damaged by ionophores. Our data strongly support the downstream exploration of monovalent ionophores for repositioning as new antimalarial and transmission-blocking leads.

scholarly journals Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Yongzhe Zhang ◽  
Fei Liu ◽  
Yan Zhao ◽  
Fan Yang ◽  
Jie Bai ◽  
...  
Keyword(s):  
Amino Acids ◽  
Plasmodium Vivax ◽  
Recombinant Proteins ◽  
Expression System ◽  
Anopheles Dirus ◽  
Transmission Blocking ◽  
Yeast Expression System ◽  
Membrane Feeding ◽  
Reducing Activity ◽  
Membrane Feeding Assay

Abstract Background Plasmodium vivax transmission-blocking vaccines (TBVs) are receiving increasing attention. Based on excellent transmission-blocking activities of the PbPH (PBANKA_0417200) and PbSOP26 (PBANKA_1457700) antigens in Plasmodium berghei, their orthologs in P. vivax, PVX_098655 (PvPH) and PVX_101120 (PvSOP26), were selected for the evaluation of their potential as TBVs. Methods Fragments of PvPH (amino acids 22–304) and PvSOP26 (amino acids 30–272) were expressed in the yeast expression system. The recombinant proteins were used to immunize mice to obtain antisera. The transmission-reducing activities of these antisera were evaluated using the direct membrane feeding assay (DMFA) using Anopheles dirus mosquitoes and P. vivax clinical isolates. Results The recombinant proteins PvPH and PvSOP26 induced robust antibody responses in mice. The DMFA showed that the anti-PvSOP26 sera significantly reduced oocyst densities by 92.0 and 84.1% in two parasite isolates, respectively, whereas the anti-PvPH sera did not show evident transmission-reducing activity. The variation in the DMFA results was unlikely due to the genetic polymorphisms of the two genes since their respective sequences were identical in the clinical P. vivax isolates. Conclusion PvSOP26 could be a promising TBV candidate for P. vivax, which warrants further evaluation. Graphical Abstract

scholarly journals The Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium falciparum Transmission to Anopheles Mosquito Vector

2012 ◽  
Vol 56 (7) ◽  
pp. 3544-3548 ◽  
Author(s):  
J. C. van Pelt-Koops ◽  
H. E. Pett ◽  
W. Graumans ◽  
M. van der Vegte-Bolmer ◽  
G. J. van Gemert ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Drug Candidate ◽  
Mosquito Vector ◽  
Content Type ◽  
Membrane Feeding ◽  
Dose Dependent Fashion ◽  
Dose Dependent ◽  
Membrane Feeding Assay ◽  
Reducing Potential

ABSTRACTThe global malaria agenda has undergone a reorientation from control of clinical cases to entirely eradicating malaria. For that purpose, a key objective is blocking transmission of malaria parasites from humans to mosquito vectors. The new antimalarial drug candidate NITD609 was evaluated for its transmission-reducing potential and compared to a few established antimalarials (lumefantrine, artemether, primaquine), using a suite ofin vitroassays. By the use of a microscopic readout, NITD609 was found to inhibit the early and late development ofPlasmodium falciparumgametocytesin vitroin a dose-dependent fashion over a range of 5 to 500 nM. In addition, using the standard membrane feeding assay, NITD609 was also found to be a very effective drug in reducing transmission to theAnopheles stephensimosquito vector. Collectively, our data suggest a strong transmission-reducing effect of NITD609 acting against differentP. falciparumtransmission stages.

scholarly journals N-Terminal Prodomain of Pfs230 Synthesized Using a Cell-Free System Is Sufficient To Induce Complement-Dependent Malaria Transmission-Blocking Activity

2011 ◽  
Vol 18 (8) ◽  
pp. 1343-1350 ◽  
Author(s):  
Mayumi Tachibana ◽  
Yimin Wu ◽  
Hideyuki Iriko ◽  
Olga Muratova ◽  
Nicholas J. MacDonald ◽  
...  
Keyword(s):  
Malaria Transmission ◽  
Expression System ◽  
Surface Protein ◽  
Western Blot Assay ◽  
Free System ◽  
Transmission Blocking ◽  
Content Type ◽  
Membrane Feeding ◽  
Blocking Activity ◽  
Transmission Blocking Vaccine

ABSTRACTThe aim of a malaria transmission-blocking vaccine is to block the development of malaria parasites in the mosquito and thus prevent subsequent infection of the human host. Previous studies have demonstrated that the gametocyte/gamete surface protein Pfs230 can induce transmission-blocking immunity and have evaluatedEscherichia coli-produced Pfs230 as a transmission-blocking vaccine candidate. In this study, we used the wheat germ cell-free expression system to produce N-terminal fragments of Pfs230 and evaluated the transmission-blocking activity of antisera raised against the recombinant Pfs230 protein. The rabbit antisera reacted to the surface of cultured gametocytes and gametes of thePlasmodium falciparumNF54 line, recognized the 360-kDa form of parasite-produced Pfs230 by Western blot assay, and reduced the infectivity of NF54 parasites toAnopheles stefensimosquitoes in the presence of complement in a standard membrane feeding assay. Thus, our data demonstrate that the N-terminal pro domain of Pfs230 is sufficient to induce complement-dependent transmission-blocking activity againstP. falciparum.

scholarly journals Imaging-Based High-Throughput Screening Assay To Identify New Molecules with Transmission-Blocking Potential against Plasmodium falciparum Female Gamete Formation

2015 ◽  
Vol 59 (6) ◽  
pp. 3298-3305 ◽  
Author(s):  
Celia Miguel-Blanco ◽  
Joël Lelièvre ◽  
Michael J. Delves ◽  
Ana I. Bardera ◽  
Jesús L. Presa ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Drug Discovery ◽  
High Throughput ◽  
High Throughput Screening ◽  
Female Gamete ◽  
Transmission Blocking ◽  
Content Type ◽  
Female Gametocyte ◽  
Gamete Formation ◽  
Selection Of

ABSTRACTIn response to a call for the global eradication of malaria, drug discovery has recently been extended to identify compounds that prevent the onward transmission of the parasite, which is mediated byPlasmodium falciparumstage V gametocytes. Lately, metabolic activity has been usedin vitroas a surrogate for gametocyte viability; however, as gametocytes remain relatively quiescent at this stage, their ability to undergo onward development (gamete formation) may be a better measure of their functional viability. During gamete formation, female gametocytes undergo profound morphological changes and express translationally repressed mRNA. By assessing female gamete cell surface expression of one such repressed protein, Pfs25, as the readout for female gametocyte functional viability, we developed an imaging-based high-throughput screening (HTS) assay to identify transmission-blocking compounds. This assay, designated theP. falciparumfemale gametocyte activation assay (FGAA), was scaled up to a high-throughput format (Z′ factor, 0.7 ± 0.1) and subsequently validated using a selection of 50 known antimalarials from diverse chemical families. Only a few of these agents showed submicromolar 50% inhibitory concentrations in the assay: thiostrepton, methylene blue, and some endoperoxides. To determine the best conditions for HTS, a robustness test was performed with a selection of the GlaxoSmithKline Tres Cantos Antimalarial Set (TCAMS) and the final screening conditions for this library were determined to be a 2 μM concentration and 48 h of incubation with gametocytes. TheP. falciparumFGAA has been proven to be a robust HTS assay faithful toPlasmodiumtransmission-stage cell biology, and it is an innovative useful tool for antimalarial drug discovery which aims to identify new molecules with transmission-blocking potential.

Evaluation of two Plasmodium vivax sexual-stage antigens as transmission-blocking vaccine candidates

2021 ◽  
Author(s):  
Yongzhe Zhang ◽  
Fei Liu ◽  
Yan Zhao ◽  
Fan Yang ◽  
Jie Bai ◽  
...  
Keyword(s):  
Amino Acids ◽  
Plasmodium Vivax ◽  
Recombinant Proteins ◽  
Expression System ◽  
Transmission Blocking ◽  
Yeast Expression System ◽  
Membrane Feeding ◽  
Reducing Activity ◽  
Membrane Feeding Assay ◽  
Transmission Blocking Vaccines

Abstract Background: Plasmodium vivax transmission-blocking vaccines (TBVs) have received high attention. PVX_098655 (PvPH) and PVX_101120 (PvSOP26) were predicted to be potential TBV antigens based on the studies of their orthologs in Plasmodium berghei. Methods: Fragments of PvPH (amino acids 22–304) and PvSOP26 (amino acids 30–272) were expressed in the yeast expression system. The recombinant proteins were used to immunize mice to obtain the antisera. The transmission-reducing activities of these antisera were evaluated using the standard membrane feeding assay (SMFA) using Anopheles dirus mosquitoes and P. vivax clinical isolates. Results: The recombinant proteins PvPH and PvSOP26 induced robust antibody responses in mice. With SMFA, the anti-PvSOP26 sera significantly reduced oocyst densities by 92.0% and 84.1% in two parasite isolates, while the anti-PvPH sera did not show evident transmission-reducing activity. Both PvPH and PvSOP26 showed limited gene polymorphisms in the clinical P. vivax isolates. Conclusion: PvSOP26 could be a promising TBV candidate for P. vivax.

Sign in / Sign up

Export Citation Format

Share Document